Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors

AIDS Reviews

Volumn 6, Issue 4, 2004, Pages 208-217

  Jackson, Akil ^a   Taylor, Stephen ^b   Boffito, Marta ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Drug drug interactions; Pharmacodynamics; Pharmacokinetics; Protease inhibitors

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTACID AGENT; ATAZANAVIR; ATORVASTATIN; BILIRUBIN; CANNABINOID; CYTOCHROME P450; DIDANOSINE; EFAVIRENZ; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR; METHADONE; MEVINOLIN; NELFINAVIR; PHOSPHATE BINDING AGENT; PRAVASTATIN; PROTEINASE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RANITIDINE; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG;

AREA UNDER THE CURVE; CELL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSFORMATION; ENZYME INHIBITION; FATIGUE; HERBAL MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IN VIVO STUDY; KIDNEY DISEASE; LIVER DYSFUNCTION; META ANALYSIS; MOLECULAR MECHANICS; NAUSEA; PREDICTION; REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 13644266465     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004;292:251-65.
2. Patick A, Potts K. Protease inhibitors as antiviral agents. Clin Microbiol Rev 1998;11:614-27.
3. Gerber J. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of HIV infection. Clin Infect Dis 2000;30 Suppl 2:123-9.
4. Piscitelli S, Gallicano K. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
5. Moyle G, Back D. Principles and practice of HIV protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-13.
6. Hsu A, Granneman G, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998;42:2784-91.
7. Flexner C. HIV protease inhibitors. N Engl J Med 1998;338:1281-92.
8. Eagling V, Back D, Barry M. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-4.
9. Molla A, Mo H, Vasavanonda S, et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 2002;46:2249-53.
10. Pirmohamed M, Back D. The pharmacogenomics of HIV therapy. Pharmacogenomics J 2001;1:243-53.
11. Hammer S, Vaida F, Bennett K, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002;288:169-80.
12. Stazsewski S, Dauer B, Carlebach A. The LOPSAQ salvage study: 48-week analysis of the full cohort treated with lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy. XV International AIDS Conference; 2004; Bangkok.
13. Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004;18:503-8.
14. Ribera E, López R, Díaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in HIV-infected adults. Antimicrob Agents Chemother 2004;48:4256-62.
15. Stazsewski S, Dauer B, Carlebach A. The LOPSAQ: 12-hour pharmacokinetic analysis of HIV+ patients treated with the salvage regimen lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004; Rome.
16. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004;18:1291-7.
17. Kilby J, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002;3:97-104.
18. Von Hentig N, Mueller A, Haberl A. The ATSAQ-1 cohort study: Pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor therapy regime. XV International AIDS Conference; 2004; Bangkok.
19. Boffito M, Maitland D, Dickinson L, et al. Pharmacokinetics (PK) of saquinavir hard gel (SQV)/ritonavir (r) in combination with different doses of atazanavir (ATV) once daily (OD) in HIV+ patients. 7th International Congress on Drug Therapy in HIV Infection; 2004; Glasgow.
20. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003;4 Suppl 1:1-41.
21. Tremblay C, Merrill D, Chou T. Two- and three-protease inhibitor combinations against zidovudine-sensitive and zidovudine-resistant HIV-1 isolates in vitro. 12th World AIDS Conference; 1998; Geneva.
22. St. Clair M, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996;29:53-6.
23. Furfine E, Berrey M, Naderer O. Virologic and pharmacokinetic rationale for a new salvage regimen: APV/SQV/RTV BID. 3rd International Workshop on Salvage Therapy for HIV Infection; April 12-14, 2000; Chicago (IL).
24. Sadler B, Gillotin C, Lou Y, Stein D. Pharmacokinetic and pharmacodynamic study of the HIV protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001;45:30-7.
25. Corbett A, Eron J, Fiscus S, Rezk N, Kashuba A. The pharmacokinetics, safety, and initial virologic response of a triple protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2004;36:921-8.
26. Boffito M, Dickinson L, Hill A, et al. Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;37:1376-84.
27. Mauss S, Schmutz G, Kuschak D. Unfavorable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS 2002;16:296-7.
28. Khanlou H, Graham E, Brill M, Farthing C. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002;16:797-8.
29. De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Hoetelmans R, Cauda R. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr 2004;35:359-66.
30. Taburet A, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with HIV. Clin Pharmacol Ther 2004;75:310-23.
31. Raguin G, Chene G, Morand-Joubert L, et al. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther 2004;9:615-25.
32. Wire M, Naderer O, Masterman A. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV10011 and APV10012). 11th CROI; 2004; San Francisco (CA).
33. Corbett A, Davidson L, Park J. Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir, lopinavir and ritonavir. 11th CROI; 2004; San Francisco (CA).
34. Back D, Blaschke T, Boucher C. Optimizing TDM in HIV clinical care; a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. HIV Pharmacology Workshop; 2004; Rome.
35. Antoniou T, Tseng A, Van Heeswijk R. Steady-state pharmacokinetics (PK) and tolerability of indinavir (IDV) when co-administered with lopinavir/ritonavir (LPV/r) in experienced subjects. 4th International Workshop on Clinical Pharmacology of HIV Therapy; 2003; Cannes.
36. Bertz R, Foit C, Ashbrenner E. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. 42nd ICAAC; 2002; San Diego (CA).
37. Isaac A, Taylor S, Rubin G. Lopinavir/ritonavir combined with twice-daily indinavir: pharmacokinetics in blood, CSF and semen (The Protect study). 10th CROI; 2003; Boston (MA).
38. Gathe J, Kohlbrenner V, Pierone G. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients BI 1182.52. 10th CROI; 2003; Boston (MA).
39. Leith J, Walmsley S, Katlama C. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV) amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004; Rome.
40. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir/ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47:350-9.
41. Company BMS. Reyataz (atazanavir). Summary of product characteristics. Princeton, NJ: Bristol Meyer Squibb Company; 2004.
42. Wire M, Ballow C, Preston S, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004;18:897-907.
43. DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. 24-Week efficacy and safety data of 908/r versus LPV/r in PI-experienced subjects. 10th CROI; 2003; Boston (MA).
44. Kearney B, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long-term safety profile of tenofovir DF and lopinavir/ritonavir. 43rd ICAAC; 2003; Chicago (IL).
45. Poirier J, Meynard J, Guiard-Schmid J, Girard P, Rozenbaum W, Jaillon P. Lack of alteration of lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and Tenofovir DF. 42nd ICAAC; 2002; Chicago (IL).
46. Cundy K. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999;36:127-43.
47. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller D. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999;56:383-9.
48. Creput C, González-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:935-7.
49. Verhelst D, Monge M, Meynard J, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3.
50. Coca S, Perazella M. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002;324: 342-4.
51. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-3.
52. Murphy M, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003;36:1082-5.
53. Fichtenbaum C, Gerber J. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-211.
54. Fichtenbaum C, Gerber J, Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 2002;16:569-77.
55. Mathews W, McCutchan J, Asch S, et al. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization study. Med Care 2000;38:750-62.
56. min and AUC were similar to historical control when IDV administered with 200 mg RTV. 43rd ICAAC; 2003;Chicago (IL).
57. Ford S, Wire M, Lou Y, Backer K, Stein D. The effect of antacids and ranitidine on the pharmacokinetics (PK) of GW433908 (908) (APV10007). 43rd ICAAC; 2003; Chicago (IL).
58. Bertz R, Chiu Y, Naylor C, Luff K, Brun S. Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. 7th International Congress on Drug Therapy in HIV infection; 2004; Glasgow.
59. Van Heeswijk R, Sabo J, Cooper C, et al. The pharmacokinetic interaction between tipranavir/ritonavir (500/200) bid and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004; Rome.
60. Kosel B, Aweeka F, Benowitz N, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002;16:543-50.
61. Hendrix C, Wakeford J, Wire M, Bigelow G, Cornell E, Christopher J. Pharmacokinetic and pharmacodynamic evaluation of methadone enantiomers following co-administration with amprenavir in opioid-dependent subjects. 40th ICAAC; 2000; Toronto.
62. Cantilena L, McCrea J, Blazes D, Winchell G, Carides A, Royce C. Lack of a pharmacokinetic interaction between indinavir and methadone. Clin Pharmacol Therapeutics 1999;65:135.
63. McCance-Katz E, Rainey P, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003;37:476-82.
64. Bertz R, Hsu A, Lam W, Williams L, Renz C, Karol M. Pharmacokinetic interaction between lopinavir/ritonavir (ABT-378/r) and other non-HIV drugs. 5th International Congress on Drug Therapy in HIV Infection; 2000; Glasgow.
65. Hsyu P, Lillibridge J, Maroldo L, Weiss W. Pharmacokinetic and pharmacodynamic interactions between nelfinavir and methadone. 7th CROI; 2000; San Francisco (CA).
66. Smith P, Booker B, DiFrancesco R, Morse G, Cottone P, Murphy M. Effect of methadone or LAAM on the pharmacokinetics of nelfinavir and M8. 41st ICAAC; 2001; Chicago (IL).
67. Gerber J, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 2001;27:153-60.
68. Munsiff A, Patel J. Regimens with once-daily ritonavir/Fortovase are highly effective in PI-experienced HIV-HCV coinfected patients on methadone. 39th Annual Meeting of the Infectious Diseases Society of America; 2001; San Francisco (CA).
69. IDSA Panel. Primary care guidelines for the management of persons infected with HIV: recommendations of the HIV Medicine Association of the IDSA. Clin Infect Dis 2004;39:609-29.
70. Piscitelli S, Burstein A, Chaitt D, Alfaro R, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-8.
71. Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-11.
72. Piscitelli S, Burstein A, Welden N, Gallicano K, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-8.
73. Kupferschmidt H, Fattinger K, Ha H, Follath F, Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998;45:355-9.
74. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-95.